ArticleCancer discovery2018
A Secondary Mutation in
Open access · bronzeAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.Neuro-oncology · 2022Pooled it
- Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).International journal of oncology · 2026Review
- New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.Cancer science · 2026Review
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Management of asynchronous multifocal adult glioblastoma with loss of BRAFActa neuropathologica communications · 2025Article
- Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.Journal of neuro-oncology · 2025Article
- MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.Molecular cancer therapeutics · 2024Article
- BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamicsMolecular therapy. Oncology · 2024Article
- BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Nature reviews. Clinical oncology · 2024Review
- Research progress on the multi-omics and survival status of circulating tumor cells.Clinical and experimental medicine · 2024Review
- Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.Current medicinal chemistry · 2024Article
- Acquired and intrinsic resistance to vemurafenib in BRAFFEBS open bio · 2024Article
- H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Article
- Review
- Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.Cancers · 2023Review
- Targeting mitochondrial metabolism for metastatic cancer therapy.Molecular carcinogenesis · 2022Review
- A saturation mutagenesis screen uncovers resistant and sensitizing secondaryProceedings of the National Academy of Sciences of the United States of America · 2022Article
- BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution.Frontiers in oncology · 2022Review
- Resistance mechanisms in BRAFFrontiers in oncology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 3 institutions in 1 country.
Jiawan WangDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Zhan YaoMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip JonssonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Amy N AllenDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Alice Can Ran QinDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Sharmeen UddinMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ira J DunkelDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-8091-6067
Mary PetriccioneDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Katia ManovaDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sofia HaqueDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc K RosenblumDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
David J PisapiaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
Neal RosenMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Christine A PratilasDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. cpratil1@jhmi.edu.
Memorial Sloan Kettering Cancer Center · USSidney Kimmel Comprehensive Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MFeedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in humaK08CA127350 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PRATILAS, CHRISTINE ANNE · 2009 to 2013
$866kNCI NIH HHS K08 CA127350NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204749NCI NIH HHS R35 CA210085NIH HHS U54 OD020355
Abstract
BRAF
Indexed as
Drug Resistance, NeoplasmMutationAdolescentBrain NeoplasmsDisease ProgressionExome SequencingHumansImidazolesMaleOximesProtein MultimerizationProto-Oncogene Proteins B-rafBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.